To address unmet clinical needs, we proposed to augment four components of our Cyclotron and Radiochemistry Program for pediatric PET practice and research:

• Chemistry & Radiochemistry
• Clinical Radiochemistry
• Regulatory Affairs
• Dosimetry & Quantitative Data Analysis

These highly interactive components support four User Groups for Pediatric Oncology:

• Discovery (user group A): Patient-derived xenograft (PDX) models are being used to establish PET applications in Pediatric Oncology. PET studies are being complemented with metabolomics and in vivo ¹³C tracing to understand the biological implications of radiotracer uptake.
• Translational (user group B): These projects are collectively focused on the translational roles of PET in cancer diagnostics and in therapeutic regimens involving existing or novel targets in pediatric cancer. 
• Clinical (user group C): Two layers of clinical trials are being pursued: In the first 2 – 3 years, we are focusing on adding PET imaging to ongoing clinical trials. Starting from Year 3, we will initiate PET-centered clinical trials.
• Cardiotoxicity (user group D): Cardiotoxicity studies and PET-aided evaluation in animal models and pediatric cancer patients. Given the commonality of cardiotoxicity that arises from chemotherapy of pediatric cancers, the imaging-guided evaluation of molecular signatures of toxicity is facilitating dose optimization of relevant therapeutic strategies and further treatment planning.